Ensysce Biosciences, Inc. (ENSC)
Largest Insider Buys in Sector
ENSC Stock Price History Chart
ENSC Stock Performance
About Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of …
Insider Activity of Ensysce Biosciences, Inc.
Over the last 12 months, insiders at Ensysce Biosciences, Inc. have bought $0 and sold $0 worth of Ensysce Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Ensysce Biosciences, Inc. have bought $370,327 and sold $8.1M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 90,287 shares for transaction amount of $44,087 was made by GOWER BOB G (director) on 2023‑03‑02.
List of Insider Buy and Sell Transactions, Ensysce Biosciences, Inc.
| 2023-03-02 | director | 90,287 0.6576% | $0.49 | $44,087 | -71.07% | |||
| 2023-03-01 | director | 270,000 2.1241% | $0.48 | $128,979 | -68.06% | |||
| 2023-02-28 | director | 109,300 0.8628% | $0.49 | $53,371 | -68.47% | |||
| 2022-12-09 | director | 357,143 19.2974% | $1.40 | $500,000 | -83.82% | |||
| 2022-05-25 | Chief Executive Officer | 27,000 0.0797% | $0.53 | $14,216 | -78.38% | |||
| 2020-06-19 | Sale | 10 percent owner | 776,290 0.2223% | $10.44 | $8.1M | -4.82% | ||
| 2017-12-01 | 10 percent owner | 1M 4.2688% | $10.00 | $10M | +28324.91% |
Insider Historical Profitability
| HG Vora Capital Management, LLC | 10 percent owner | 3837500 294.0771% | $8.23 | 1 | 0 | |
| GOWER BOB G | director | 1222682 93.6971% | $8.23 | 4 | 0 | <0.0001% |
| Kirkpatrick Lynn | Chief Executive Officer | 381851 29.2622% | $8.23 | 1 | 0 |